VICTORIA
MK-1242 Vericiguat or Placebo qd – Visits every 2 weeks for the first 2 visits and every 4 months thereafter up to approximately 39 months. Rationale: The VICTORIA trial will evaluate the clinical efficacy of vericiguat on a background of HF standard therapy for subjects with HFrEF.
PHASE: Enrolling
Principal Investigator:
Brendan Cavanaugh, MD, FACC
Sub-Investigators:
Sean Mazer, MD, FHRS, FACC
Michael Bestawros, MD, MPH
Karen Sopko, MD, FACC
Yaw Adjei-Poku, MD
Mridula Rai, MD, FACC
Faisal Zaeem, MD
Laura McDermott, CNP, MSN, CACP
PRIME-HF (Congestive Heart Failure)
Study to evaluate Post-Acute Heart Failure Syndrome with left ventricular ejection fraction (LVEF) <35%, New York Heart Association (NYHA) class II-IV symptoms despite guideline-directed medical therapy, documented clinical stability, and sinus rhythm with a resting heart rate of >70 beats per minute (bpm).
PHASE: Enrolling
Principal Investigator:
Brendan J. Cavanaugh, MD, FACC
Sub-Investigators:
Mihaela Bujoi, MD, FACC
Karen Sopko, MD, FACC
CANTOS
A randomized, double blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.
PHASE: Follow Up (no longer accepting new patients)
Principal Investigator:
Karen Sopko, MD, FACC
Sub-Investigators:
Mark Bieniarz, MD, FACC, FSCAI
Brendan Cavanaugh, MD, FACC
PARAGON
This study is a multi-center, randomized, double-blind, parallel group, active comparator, morbidity and mortality trial designed to evaluate the efficacy and safety of LCZ696 compared to valsartan in HFpEF patients (NYHA class II-IV).
PHASE: Follow Up (not taking new patients)
Principal Investigator:
Karen Sopko, MD, FACC
Sub-Investigators:
Mark Bieniarz, MD, FACC, FSCAI
Brendan Cavanaugh, MD, FACC
Sean Mazer, MD, FHRS, FACC
Mel Peralta, MD, FACC
Brad Gwyther, MS, PA-C